Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                International Activities

International Activities

                        Regulatory Harmonization and Convergence
          Foreign Regulators – Information and Training Resources
          Foreign Regulator Information Exchanges
          International Engagements to Respond to Covid-19 Pandemic
          Quick Guide to Web Resources
          Foreign Regulatory Seminar (Web-Based): CBERs Regulation of Biologics


                        WHO Engagements Home
          Vaccines, Blood & Biologics
          International Activities
          International Engagements to Respond to Covid-19 PandemicInternational Activities International Engagements to Respond to Covid-19 Pandemic
  
  	
    Share
    Post
    Linkedin

    Email
    PrintCBER has substantially increased its international efforts in addressing the COVID-19 pandemic.  This includes regulatory and research collaborations regarding COVID-19 vaccine and convalescent plasma products.  By providing scientific and regulatory strategies to facilitate the development, authorization, and availability of COVID-19 vaccines and treatments, CBER contributes to the reduction and spread of COVID-19.

International map with figures
During the pandemic, international regulatory agencies facing travel restrictions have shared inspection information. As with other FDA components, CBER has provided and received a wealth of inspectional information to and from its confidential partners. The CBER International Affairs Team has facilitated inspection information exchange through daily coordination and communication with international partners.

CBER participates in ongoing international pharmacovigilance efforts, including those organized by the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO). CBER’s collaborations with ICMRA facilitate information exchange during the ongoing COVID-19 pandemic among global health regulatory authorities. Also, CBER facilitates important exchanges of information and views on the following ICMRA Working Groups: COVID-19 Working Group, Pregnancy and Lactation in COVID-19, COVID-19 Pharmacovigilance Network, Observational Studies and Real World Evidence.

person in protective gear injecting a small globe
CBER has a wide range of collaborations with the WHO to support preparedness and global response to the COVID-19 pandemic. CBER is actively engaged in the R&D Blueprint discussions on prioritizing COVID-19 vaccine research to address critical issues, including response to variants, in real time. CBER experts contribute to SARS-CoV-2 standards development activities and participate as members of WHO Working Groups on animal models and immune assays – activities that are integrally linked to global COVID-19 vaccine development efforts. As a national regulatory authority of reference, CBER has a significant role in WHO’s Emergency Use Listing (EUL) of two COVID-19 vaccines that are being used globally, and which are part of the U.S. vaccine donation program to increase access to COVID-19 vaccines in all regions of the world.

CBER has been proactive in sharing information with the WHO at the global level and through regional networks. Examples include CBER’s engagement with the African Vaccine Regulatory Forum (AVAREF) and collaboration with the African Union Smart Safety Surveillance (AU-3S) program which is focused on vaccine safety monitoring as immunization programs for COVID-19 are implemented in African countries. In addition to information sharing, these multilateral collaborations contribute to regulatory systems strengthening globally and increase preparedness to respond to the current and future public health emergencies.

light bulb with map
CBER continues to engage structured scientific and policy discussions under confidentiality commitments with foreign regulatory counterparts.  For example, CBER participates in regulatory “clusters” (working groups) with international partners such as the European Medicines Agency (EMA) and the Health Products and Food Branch of Health Canada.  Clusters are made up of regulatory experts who meet routinely to discuss regulatory and scientific issues of mutual interest.  CBER is a principal participant in the Clusters for Blood Products, Advanced Therapy Medicinal Products, and Vaccines, and additionally participates as appropriate in the Agency Oncology, Pediatric, Pharmacovigilance, Biosimilar and Pharmacogenomic Clusters.

CBER participates in discussions in various cluster meetings to ensure a deeper understanding of agencies regulatory approaches and undertake mutual information sharing on COVID-19 products safety and efficacy, and inspection activities. CBER technical experts contribute to international COVID-19 vaccine safety efforts by participating in the FDA/EMA pharmacovigilance cluster.

In addition, the CBER International Affairs Team collaborates with CBER scientific experts to identify strategic technical areas across CBER for which collaboration with foreign counterparts will add value to CBER’s mission.

The information sharing mutually complements the work CBER’s COVID-19 product authorization activities.  CBER utilizes the FDA Confidentiality Commitments tools for regulatory and research exchanges.  All agency confidentiality commitments are listed on the FDA website for reference.

globe of flags

                                                                                  Content current as of:
      02/11/2022
              
              
Regulated Product(s)
		 BiologicsInternational Activities

          
                        Regulatory Harmonization and Convergence
          Foreign Regulators – Information and Training Resources
          Foreign Regulator Information Exchanges
          International Engagements to Respond to Covid-19 Pandemic
          Quick Guide to Web Resources
          Foreign Regulatory Seminar (Web-Based): CBERs Regulation of Biologics


                        WHO Engagements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop